Press Release (ePRNews.com) - TORONTO - Oct 29, 2018 - Aimed at small and mid-size companies with oncology assets, this one-hour webinar will present the theory behind early phase oncology studies, as well as the practical and logistical challenges to be prepared for when taking a compound into the clinic.
Join Dr. Alain Thibault, Senior Medical Director of early phase Oncology Trials at Simbec-Orion Group, and Dr. Ahmad Awada, Head of the Medical Oncology Clinic at Jules Bordet Cancer Institute, as they provide insights from key ESMO 2018 presentations likely to influence the future of early phase oncology drug development.
This live webinar upcoming on Wednesday, Nov. 14, 2018, at 8:30 a.m. EST (1:30 p.m. GMT/UK), will be split into four parts, including:
- An introduction into how Phase I studies have evolved to meet development objectives
- A discussion of where early phase design is heading, with a look at whether 3+3 is still the gold standard and what could replace it
- The importance of pre-feasibility consultation with specialist oncology sites
- A live Q&A with expert speakers
For more information about this complimentary webinar, visit ESMO Update: State of the Art in Early Phase Oncology Trial Design.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Nima Rajan Source :
Tel: +1 (416) 977-6555 ext 352